Cited by 96Mangiferin and Mango ExtractsNatural Antidiabetic Agents StudiesMetabolism, Diabetes, and Cancer

Mangiferin Improves Hepatic Lipid Metabolism Mainly Through Its Metabolite-Norathyriol by Modulating SIRT-1/AMPK/SREBP-1c Signaling

Open access
Li, Jian, Liu, Mengyang, Yu, Haiyang, Wang, Wei, Han, Lifeng, Chen, Qian, Ruan, Jingya, Wen, Shaoshi +2 more·2018·Frontiers in Pharmacology

Abstract

Objective: Mangiferin (MGF) is a natural xanthone, with regulation effect on lipid metabolism. However, the molecular mechanism remains unclear. We purposed after oral administration, MGF is converted to its active metabolite(s), which contributes to the effects on lipid metabolism. Methods: KK-Ay mice were used to validate the effects of MGF on lipid metabolic disorders. liver biochemical indices and gene expressions were determined. MGF metabolites were isolated from MGF administrated rat urine. Mechanism studies were carried out using HepG2 cells treated by MGF and its metabolite with or without inhibitors or small interfering RNA. Western blot and immunoprecipitation methods were used to determine the lipid metabolism related gene expression. AMP/ATP ratios were measured by HPLC. AMP-activated protein kinase (AMPK) activation were identified by homogeneous time resolved fluorescence (HTRF) assays. Results: MGF significantly decreased liver triglyceride and free fatty acid levels, increased sirtuin-1 (SIRT-1) and AMPK phosphorylation in KK-Ay mice. HTRF studies indicated that MGF and its metabolites were not direct AMPK activators. Norathyriol, one of MGF's metabolite, possess stronger regulating effect on hepatic lipid metabolism than MGF. The mechanism was mediated by activation of SIRT-1, liver kinase B1, and increasing the intracellular AMP level and AMP/ATP ratio, followed by AMPK phosphorylation, lead to increased phosphorylation level of sterol regulatory element-binding protein-1c. Conclusion: These results provided new insight into the molecular mechanisms of MGF in protecting against hepatic lipid metabolic disorders via regulating SIRT-1/AMPK pathway. Norathyriol showed potential therapeutic in treatment of non-alcoholic fatty liver disease.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fphar.2018.00201

Cites

42 of 42 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Several frequently cited mechanisms (NF-κB or MMP-9 modulation, G2/M arrest, AMPK activation) are highly context dependent and inconsistently replicated.

    “Notably, the results vary across cell lines and animal strains, and several mechanisms that are frequently cited (for example, NF-κB or MMP-9 modulation, G2/M arrest and AMPK activation) appear to be highly context dependent, with inconsistent replication under different stimuli or dosing conditions (4,13,117,124,186,187).”

    From Mangiferin in human disease: Multifaceted mechanisms and applications (Review) (2026) · cites this paper as [187]

    The Results and Discussion report that mangiferin increased AMPK phosphorylation in mouse liver, but that mangiferin and its metabolites were not direct AMPK activators; the Discussion also reports that norathyriol failed to induce AMPK phosphorylation after LKB1 knockdown. This supports a dependence on upstream signaling in the conditions studied, not the broader claim of inconsistent replication across cell lines, animal strains, stimuli, or doses. The cited passages do not address NF-κB, MMP-9, or G2/M arrest. Page numbers are unavailable in our copy. (LLM, conf=0.83)

    Experimental — accuracy not yet measured
  • Results vary across cell lines and animal strains.

    “Notably, the results vary across cell lines and animal strains, and several mechanisms that are frequently cited (for example, NF-κB or MMP-9 modulation, G2/M arrest and AMPK activation) appear to be highly context dependent, with inconsistent replication under different stimuli or dosing conditions (4,13,117,124,186,187).”

    From Mangiferin in human disease: Multifaceted mechanisms and applications (Review) (2026) · cites this paper as [187]

    The Materials and Methods (In Vivo Studies; page unavailable) use KK-Ay mice for mangiferin treatment and C57BL/6 mice as normal controls; the Results describe experiments in HepG2 cells. These passages do not compare treatment results across cell lines or animal strains. A search for context-dependent results and inconsistent replication found no passage establishing the attributed claim. (LLM, conf=0.76)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

1 of the 43 references couldn’t be matched to a known paper.

Cited by

Sorted by citations

Authors
Li, J., Liu, M., Yu, H., Wang, W., Han, L., Chen, Q., Ruan, J., Wen, S., Zhang, Y., & Wang, T.
Affiliations
  • Tianjin University of Traditional Chinese Medicine (CN)
  • Houston Methodist (US)
Corresponding author
  • Zhang, Yi
  • Wang, Tao
Venue
Frontiers in Pharmacology
Published
2018-03-07
Volume
9
Pages
201-201
ISSN
1663-9812 (ISSN-L)
OpenAlex
W2789724853
Cited by
95
References
43
Citations by year
2026: 4 · 2025: 11 · 2024: 13 · 2023: 13 · 2022: 12 · 2021: 15 · 2020: 10 · 2019: 15 · 2018: 2
FWCI
14.41
Type
journal article
Language
en
Open access
Locations
  • Frontiers in Pharmacology (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
National Natural Science Foundation of China (81673703, 81173524)
Topics
  • Health Sciences › Medicine › Complementary and alternative medicine › Mangiferin and Mango Extracts
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Natural Antidiabetic Agents Studies
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
Keywords
mangiferin, norathyriol, hepatic lipid metabolism, SIRT1, AMPK, SREBP-1c, LKB1, AMP/ATP ratio, non-alcoholic fatty liver disease, KK-Ay mice, hepatic triglycerides, free fatty acids

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review